FIXX - Homology Medicines, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.17
-0.31 (-1.88%)
At close: 4:00PM EST

16.17 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close16.48
Open16.50
Bid16.19 x 1000
Ask21.00 x 1800
Day's Range16.16 - 16.72
52 Week Range11.05 - 31.80
Volume133,438
Avg. Volume347,398
Market Cap712.039M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.49
Earnings DateMar 09, 2020 - Mar 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.40
  • BioMarin to Begin Early-Stage Study on Gene Therapy for PKU
    Zacks

    BioMarin to Begin Early-Stage Study on Gene Therapy for PKU

    BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.

  • 'We will deliver in 2020,' Cambridge biotech CEO promises after 2nd trial disappointment
    American City Business Journals

    'We will deliver in 2020,' Cambridge biotech CEO promises after 2nd trial disappointment

    The CEO of a Cambridge biotech startup promised the company would “deliver in 2020” after announcing a second delay with its first-ever clinical trial.

  • Cambridge startup raises $110M for re-doseable gene therapies
    American City Business Journals

    Cambridge startup raises $110M for re-doseable gene therapies

    One of Cambridge’s emerging gene therapy startups has raised $110 million to support the company as it heads toward in-human trials. Generation Bio closed the Series C round this week, bringing in new investors T. Rowe Price, Farallon and Wellington Management, as well as previous backers Atlas Venture, Fidelity and others. The Series C round brings the total money raised by Generation Bio to more than $235 million.

  • We're Not Very Worried About Homology Medicines's (NASDAQ:FIXX) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Homology Medicines's (NASDAQ:FIXX) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • 3 Small-Cap Stocks Ready to Make a Big Splash
    TipRanks

    3 Small-Cap Stocks Ready to Make a Big Splash

    Everyone has to start somewhere. As is often repeated, today’s biggest companies came from humble beginnings, a garage being the initial home for mega corporations like Microsoft, Amazon and Disney.While it is common knowledge that the smaller the market cap, the larger the volatility, the opposite also rings true - the bigger a company becomes, the harder it gets to multiply its market cap, and therefore its share price. The trick, then, is to catch a promising stock before it explodes and to be able to reap the rewards its growth provides. But then follows the eternal question: how do we find one?TipRanks - a company that tracks and measures the performance of analysts - has a variety of tools at its disposal to find an undervalued stock. The site’s Analysts’ Top Stocks tool, which has filters such as market cap and sector, unearthed three such stocks. All three, coincidentally, currently have a Strong Buy consensus rating from the Street. Let’s get the lowdown.Dine Brands Global Inc (DIN)Despite a volatile 2019 for restaurant owner, Dine Brands, its share price is still up a very respectable 22% year-to-date. With a market cap of just $1.4 billion, the word on the Street is that the company is on its way to outstripping its small-cap status.Dine owns and franchises two restaurants, Applebee's Neighborhood Grill + Bar and International House of Pancakes (IHOP), which number in the thousands and are mostly based across the US.The company, though, has been expanding its international presence, and just this week announced the opening of its first IHOP restaurant in Lima, Peru. The new restaurant marks Dine’s 62nd restaurant in Latin America.The expansion follows October’s announcement of a deal with TravelCenters of America to open 94 IHOP restaurants at TA and Petro-branded interstate travel centers across the U.S. The agreement is IHOP’s largest in its history and significantly expands on the current 4 units at TravelCenters’ locationsRaymond James analyst Brian Vaccaro thinks the expansion bodes well, noting, “We believe IHOP remains an under-appreciated part of the Dine Brands story (even though it contributes approximately two-thirds of consolidated EBITDA) and that an acceleration in net new unit growth would benefit both EBITDA growth and broader investor sentiment towards the story.”To this end, Vaccaro reiterated an Outperform rating on DIN, alongside a price target of $95, indicating upside potential of 16%. (To watch Vaccaro’s track record, click here)Is the rest of the Street hungry for some Dine Brands? It appears so. A full house of 7 Buys bestows Strong Buy status on the restaurant owner. The average target price is $96.57, expressing the analysts’ confidence in an 18% increase over the next 12 months. (See Dine Brands stock analysis on TipRanks) Homology Medicines Inc (FIXX)With a market cap coming in at $966 million, this promising biotech has ample room for growth.Homology’s prime focus is on genetic medicines for patients with rare diseases. The company has several gene therapy and gene editing candidates in the pipeline. Recently, early efficacy and safety data from a clinical trial for HMI-102, its gene therapy for adults with PKU (phenylketonuria), exhibited promising signs. Further data is expected in mid-2020. The treatment is set to provide competition to BioMarin’s PKU gene therapy, BMN-307, which enters the clinic next year.Evercore’s Joshua Schimmer thinks “for now the FIXX horse is definitely in the race,” adding that “while the data is early, it is clearly encouraging.”“Fixx is developing a unique gene therapy and gene editing platform, with its proprietary AAVHSC vectors licensed from the City of Hope. The company will be initially targeting adult PKU patients using its gene therapy approach, with the aim of eventually advancing to pediatric patients with gene editing. Beyond PKU, excitement for the company stems from the potential to correct a wide range of genetic diseases with high precision,” the 5-star analyst said.Unsurprising, then, to find Schimmer reiterating an Outperform rating on FIXX, alongside a price target of $29. Should the target be met, investors stand to take home a nice 32% gain. (To watch Schimmer’s track record, click here)The Street is mostly in agreement with Schimmer on the early stage biotech. A Strong Buy consensus rating breaks down into 3 Buys and 1 Hold. An average price target of $32.50 indicates upside potential of 47%. (See Homology Medicines stock analysis on TipRanks) LiqTech International Inc (LIQT)The final ticker on our list has the smallest market cap of the lot. At $108 million, LiqTech qualifies rather as a ‘micro-cap’.Headquartered in Denmark, the clean technology company specializes in products for the environmental industry including ceramic membranes for liquid filtration and diesel particulate filters to control soot from diesel engines.LiqTech’s recent 3Q report included record quarterly revenue and net income. Revenue for 3Q19 was $9.7 million, representing a third consecutive quarter of record revenue. This figure is up from $9.3 million in the previous quarter and represents a 189% increase from 3Q18. Net income came in at $656,000, improving dramatically from a net loss of $922,000 in last year’s third quarter, and a big step up from $147,000 in 2Q.The fourth quarter, though, has seen LiqTech experience mechanical issues in two of the company’s four new furnaces on order. Nevertheless, Lake Street analyst Robert Brown expects LiqTech to overcome the issues. The first furnace is set for installation before the end of the year and should provide the company with an additional “$15M-$16M in quarterly revenue capacity.” With the IMO (international maritime organization) sulphur limit deadline of January 1, 2020 quickly approaching, the analyst notes “LiqTech's demand trends remain strong.”Therefore, Brown kept a Buy rating on LiqTech and a price target of $10.00, suggesting upside potential of a grand 89%. (To watch Brown’s track record, click here)According to Brown, then, LiqTech won’t be a micro-cap for much longer, but what do his colleagues think? Only 2 other analysts have kept tabs on the Scandinavian filtration wiz, but both deem LiqTech a Buy, therefore handing it a Strong Buy consensus rating. An average price target of $9.33 implies gains of 79% could be in the cards over the next year. (See LiqTech price targets and analyst ratings on TipRanks)

  • Benzinga

    Homology Medicines' Gene Therapy For Phenylketonuria Found Safe, Efficacy Data Mixed

    Bedford, Massachusetts-based Homology announced initial Phase 1/2 data from the pheNIX trial that evaluated its HMI-102 gene therapy in patients with phenylketonuria, with safety data showing that HMI-102 was well-tolerated. The efficacy data was mixed, with the Cohort 1 patients not showing a reduction in phenylalanine through weeks 10 and 12. Additionally, the first patient dosed in Cohort 2 also showed increases in tyrosine levels of 72% and 85% at weeks one and four, respectively, which suggests increased PAH enzyme activity.

  • Benzinga

    The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 17) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...

  • GlobeNewswire

    Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today promising initial clinical data from the first gene therapy clinical trial in phenylketonuria (PKU). The pheNIX trial is a Phase 1/2 randomized, concurrently controlled, dose-escalation study for adults with PKU.

  • GlobeNewswire

    Homology Medicines Announces Peer-Reviewed Publication of Five-Year Retrospective Study Conducted in Collaboration with Two PKU Key Opinion Leaders Demonstrating Substantially Elevated Phe Levels in Adults with Classical PKU on Standard of Care

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today a peer-reviewed publication of findings from a five-year retrospective chart review that demonstrated phenylalanine (Phe) concentrations remain elevated in adult patients with classical phenylketonuria (PKU) even when closely monitored and on the standard of care highly restricted protein diet. Elevated Phe can cause neurocognitive deficits and, as diet alone is often insufficient for achieving target Phe levels, these data support the need for new therapies to control Phe levels in patients with PKU.

  • Homology Medicines, Inc. (FIXX): Are Hedge Funds Right About This Stock?
    Insider Monkey

    Homology Medicines, Inc. (FIXX): Are Hedge Funds Right About This Stock?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

  • GlobeNewswire

    Homology Medicines Announces Appointment of Gabriel M. Cohn, M.D., as Chief Medical Officer

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that it has appointed Gabriel M. Cohn, M.D., M.B.A., as Chief Medical Officer. Dr. Cohn will join Homology’s senior management team to direct all clinical development and operations related to Homology’s dual gene therapy and gene editing technology platform.

  • GlobeNewswire

    Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs

    BEDFORD, Mass., Nov. 26, 2019 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its proprietary.

  • Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates

    Homology Medicines (FIXX) delivered earnings and revenue surprises of -15.52% and 17.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Homology Medicines Reports Third Quarter 2019 Financial Results and Recent Highlights

    Expects to Report Initial Clinical Data from Phase 1/2 pheNIX PKU Gene Therapy Clinical Trial by Year-End Presented Preclinical Data Demonstrating Progress in MLD Gene Therapy.

  • Earnings Preview: Homology Medicines (FIXX) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Homology Medicines (FIXX) Q3 Earnings Expected to Decline

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Hedge Funds Have Never Been This Bullish On Homology Medicines, Inc. (FIXX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Homology Medicines, Inc. (FIXX)

    Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]

  • GlobeNewswire

    Homology Medicines Presents Preclinical Data From Its Investigational PKU Gene Editing Program, Demonstrating Phenotypic Correction and Molecular Confirmation of Editing Precision

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today the oral presentation of preclinical data related to its nuclease-free, homologous recombination-based, in vivo gene editing program for phenylketonuria (PKU) at the European Society of Gene & Cell Therapy (ESGCT) 27th Annual Congress. Homology also presented preclinical data that showed the effect of full and empty capsids on in vivo efficacy with Homology’s adeno-associated virus vectors derived from human hematopoietic stem cells (AAVHSCs), including its investigational phenylketonuria (PKU) gene therapy candidate HMI-102, and comparisons to an AAV5 PKU gene therapy vector.

  • GlobeNewswire

    Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time Therapies

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today the presentation of preclinical data that support its investigational gene therapy programs for the treatment of metachromatic leukodystrophy (MLD) and phenylketonuria (PKU) at the American Society of Human Genetics (ASHG) 2019 Meeting. For the first time, Homology presented preclinical data from the murine model and non-human primates that demonstrated that the HMI-202 gene therapy candidate crossed the blood-brain-barrier and the blood-nerve-barrier and increased levels of arylsulfatase a (ARSA) protein to therapeutic levels.

  • GlobeNewswire

    Homology Medicines to Participate in Conferences in October

    BEDFORD, Mass., Sept. 30, 2019 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today presentations at the following industry, investor and.

  • Imagine Owning Homology Medicines (NASDAQ:FIXX) And Wondering If The 19% Share Price Slide Is Justified
    Simply Wall St.

    Imagine Owning Homology Medicines (NASDAQ:FIXX) And Wondering If The 19% Share Price Slide Is Justified

    It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...

  • GlobeNewswire

    Homology Medicines to Participate at Upcoming Investor Conferences

    BEDFORD, Mass., Sept. 03, 2019 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in two upcoming.

  • GlobeNewswire

    Homology Medicines Reports Second Quarter 2019 Financial Results and Recent Highlights

    - Phase 1/2 pheNIX Study of HMI-102 Gene Therapy Candidate for Adults with PKU Continues, Additional Sites Enrolling and Initial Data Expected by Year End -            - Fast.

  • Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Homology Medicines to Participate at Upcoming Conferences

    BEDFORD, Mass., Aug. 01, 2019 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a fireside.

  • GlobeNewswire

    Homology Medicines Appoints Alise Reicin, M.D., to the Board of Directors

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that Alise Reicin, M.D., has been appointed to its Board of Directors. Dr. Reicin is the President, Global Clinical Development at Celgene Corporation where she is responsible for mid- to late-stage clinical development across Celgene’s portfolio and is a member of the company’s Executive Committee.